Loading
The trial that proved a TROP2 ADC could nearly double survival in heavily pretreated triple-negative breast cancer.
ASCENT, trial NCT02574455 sponsored by Gilead through Immunomedics and published in the New England Journal of Medicine in 2020, proved that the TROP2 antibody-drug conjugate sacituzumab govitecan could nearly double survival in heavily pretreated metastatic triple-negative breast cancer. It randomised 529 patients with at least two prior lines to sacituzumab govitecan or chemotherapy, met its primary progression-free survival endpoint in patients without brain metastases and showed a large overall survival benefit with a much higher response rate, regardless of TROP2 expression level, which shaped the view that immunohistochemistry selection is unnecessary for TROP2 ADCs. Whether TROP2 ADCs work equally well after other topoisomerase payloads is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
529 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (patients without brain metastases)primary | Sacituzumab govitecan | 235 | 5.6 months | 0.41 (0.32 to 0.52) | <0.001 | link |
| Chemotherapy (TPC) | 233 | 1.7 months | ||||
| Overall survival | Sacituzumab govitecan | - | 12.1 months | 0.48 (0.38 to 0.59) | <0.001 | link |
| Chemotherapy (TPC) | - | 6.7 months | ||||
| Objective response rate | Sacituzumab govitecan | - | 35% | - | - | link |
| Chemotherapy (TPC) | - | 5% |
Sacituzumab govitecan is a standard second-line or later treatment for metastatic triple-negative breast cancer, roughly doubling survival compared with the chemotherapies it was tested against. Patients should expect neutropenia and diarrhoea, which are manageable with growth factor support and loperamide. Trials are now testing it earlier, in first-line combinations with pembrolizumab and after surgery for residual disease.
TROP2 IHC does not gate sacituzumab govitecan: the label requires no test, and the corpus records TROP2 as an expression readout without a threshold.
The document that made immunotherapy, PARP inhibition and the first antibody-drug conjugate the European standard for metastatic triple-negative disease; every later first-line change is an amendment to it.
Shares TROP2 PET to choose and sequence TROP2 ADCs, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer.
Shares HER2-low eligibility for trastuzumab deruxtecan, and TROP2 ADCs without a test (triple-negative disease), Palliation in advanced triple-negative breast cancer: brain, bone, pleura, skin and end of life, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer.
Shares TROP2 PET to choose and sequence TROP2 ADCs, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer.
Shares ASCENT-03, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer, TROP2.
Shares TROP2 PET to choose and sequence TROP2 ADCs, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, TROP2, Sacituzumab govitecan.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Metastatic triple-negative breast cancer, Topoisomerase-I inhibitors (and ADC payloads).
Shares ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer, KEYNOTE-119, ASCENT-04 / KEYNOTE-D19, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Metastatic triple-negative breast cancer, Topoisomerase-I inhibitors (and ADC payloads).